China FDA Launches Major Enforcement Campaign; Official Cautions Rainy Days Ahead
This article was originally published in The Gold Sheet
Executive Summary
If a widening anti-bribery investigation, a new drug cost survey and looming pricing reform is not enough, China FDA just launched its first major campaign to root out violations in pharmaceutical manufacturing and distribution. Industry needs to get ready for rainy days, an official cautioned.
You may also be interested in...
Chinese SFDA Deputy Director Under Investigation For Corruption
BEIJING - A deputy director of China's State FDA is under investigation by the Communist Party's top anti-corruption commission, which could have broad ramifications for the drug agency's daily operations
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.